The Alzheimer's Disease Research Center at the University of California, Irvine

加州大学欧文分校阿尔茨海默病研究中心

• 批准号: 9922099
• 负责人: FRANK M LAFERLA
• 金额: $ 288.37万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9922099
• 关键词: Address; Adult; Advisory Committees; Age; Aged, 80 and over; Alleles; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease risk; Alzheimer' s disease therapy; Asian Americans; Autopsy; Basic Science; Biological Markers; Blood; Brain Diseases; Brain Pathology; California; Clinical; Clinical Research; Clinical Sciences; Clustered Regularly Interspaced Short Palindromic Repeats; Cognitive; Communities; Complex; Computer software; Consent; County; Data; Data Analyses; Data Set; Dementia; Development; Diagnosis; Dimensions; Disease; Down Syndrome; Education; Ensure; Epidemic; Ethics; Ethnic group; Etiology; Faculty; Genetic; Goals; Image; Impaired cognition; Individual; Infrastructure; International; Knowledge; Leadership; Longevity; Mission; Modernization; Molecular; Nature; Older Population; Oranges; Outcome; Participant; Pathogenesis; Pathologic; Pathway interactions; Patients; Play; Populations at Risk; Predisposition; Productivity; Protocols documentation; Recording of previous events; Registries; Research; Research Methodology; Research Personnel; Resources; Role; Scholarship; Science; Scientist; Societies; Stains; Sum; Technology; Training; Translational Research; Universities; Vision; Work; aging population; biomarker development; brain tissue; cell bank; cohort; data management; data resource; education research; effective therapy; in vivo; induced pluripotent stem cell; innovation; insight; interdisciplinary approach; interdisciplinary collaboration; meetings; mild cognitive impairment; multidisciplinary; named group; neuroimaging; neuroimaging marker; neuropathology; next generation; novel; novel diagnostics; open source; participant retention; prevent; prodromal Alzheimer' s disease; recruit; resilience; stem cell biology; success

UCI ADRC Overall Project Summary/Abstract The central theme of the University of California, Irvine Alzheimer's Disease Research Center (UCI ADRC) is to identify, quantify, and validate factors that influence the risk of Alzheimer's disease (AD) across the lifespan. Given its diverse and multifactorial nature, it is critical to understand the etiology and progression of this insidious brain disorder at multiple dimensions, including clinically and neuropathologically, and to employ novel scientific approaches so that we can advance knowledge and better diagnose, prevent and cure the disease. The UCI ADRC has a strong history of integrating basic, clinical, and translational science to gain insights into AD pathogenesis and to help meet some of the goals of the National Alzheimer's Project Act. First, our Center has a distinguished record of studying the disease in diverse patient cohorts: Uniform Data Set (UDS) Cohort, which includes cognitively normal individuals and individuals with mild cognitive impairment (prodromal AD); adults with Down syndrome, representing the largest genetically at-risk population for AD; and 90+, which show great disparity between AD pathology and cognitive loss and are among the oldest group of individuals to develop AD. Together, these cohorts enable interrogation of important novel questions related to age, susceptibility and resilience, using innovative outcomes ranging from in vivo biomarker characterization to modern pathological outcomes such as post-mortem imaging and microglial staining. Second, the UCI ADRC has a history of innovation that has helped advance the field; the development of the nation's first induced pluripotent stem cell bank for AD as part of the ADRC network and our recently established Consent-to- Contact recruitment registry are recent examples of this innovation. Third, our Center continues to evolve. Given the expertise, productivity, and resources devoted the study of special populations at UCI, we have initiated two Special Populations Cores, one focused on Down syndrome and one focused on the oldest old (90+). These Cores will interact with the other cores of the ADRC to produce novel data and resources available to ADRC investigators, including through our newly established Biomarker Core. Finally, we have established a new Research and Education Component in this proposal, which harnesses the long-standing passionate commitment to training the next generation of clinicians and scientists at UCI. In sum, the UCI ADRC brings energetic and innovative multi-dimensional and multidisciplinary approaches toward addressing the national epidemic of AD.

UCI ADRC总体 项目摘要/摘要 加利福尼亚大学尔湾阿尔茨海默氏病研究中心（UCI ADRC）的中心主题是 确定，量化和验证影响整个生命周期中阿尔茨海默氏病（AD）风险的因素。 鉴于其多样化和多因素的性质，了解这一点的病因和进步至关重要 在多个维度（包括临床和神经病理学上）的阴险性脑疾病，并采用 新颖的科学方法，以便我们可以提高知识并更好地诊断，预防和治愈 疾病。 UCI ADRC在整合基础，临床和转化科学以获得的历史上有很强的历史 洞悉AD发病机理，并帮助实现《国家阿尔茨海默氏症计划法》的一些目标。 首先，我们的中心在研究多样的患者队列中研究该疾病的杰出记录：统一数据 Set（UDS）队列，包括认知正常的个体和有轻度认知障碍的个体 （前驱AD）；患有唐氏综合症的成年人，代表AD的遗传风险最大；和 90+，在AD病理学和认知损失之间显示出很大的差异，并且是最古老的群体 个人开发广告。这些队列共同审问了与 年龄，敏感性和韧性，使用创新的结果，从体内生物标志物表征到 现代病理结果，例如验尸成像和小胶质染色。第二，UCI ADRC 有创新历史，有助于发展该领域。国家首次引起的发展 作为ADRC网络的一部分，多能AD的干细胞库以及我们最近确定的同意 接触招聘注册表是这项创新的最新示例。第三，我们的中心继续发展。 鉴于专业知识，生产力和资源专门研究了UCI的特殊人群，我们有 发起了两个特殊人群，一个专注于唐氏综合症，另一个专注于最古老 （90+）。这些核心将与ADRC的其他核心相互作用，以产生新的数据和资源 ADRC调查人员可供选择，包括我们新成立的生物标志物核心。最后，我们有 在该提案中建立了一个新的研究和教育部分，该提案利用了长期的 热情地致力于培训UCI的下一代临床医生和科学家。总而言之 ADRC带来充满活力和创新的多维和多学科方法来解决 广告的全国流行病。